A vs. ALNY: Agilent vs. Alnylam Pharmaceuticals Stock Comparison

November 11, 2026

How do Agilent (A) and Alnylam Pharmaceuticals (ALNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Alnylam Pharmaceuticals (ALNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while ALNY is classified in Biotechnology.

Company profile comparison for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Profile Item	A	ALNY
Name	AgileThought, Inc. Class A Common Stock	Alnylam Pharmaceuticals, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	49.28 billion USD	20.89 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	November 18, 1999	June 1, 2004
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ALNY

GSPC

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Agilent (A) and Alnylam Pharmaceuticals (ALNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Agilent (A) and Alnylam Pharmaceuticals (ALNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
Total Return (1Y)	22.92%	-64.57%
Total Return (3Y, Annualized)	19.33%	-1.58%
Total Return (5Y, Annualized)	3.03%	-3.13%

Risk Profile

Drawdown History

ALNY

GSPC

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Agilent (A) and Alnylam Pharmaceuticals (ALNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
Volatility (1Y, Annualized)	33.10%	54.08%
Beta (5Y)	1.22	0.45
Max Drawdown (5Y)	-38.09%	-68.25%
Avg. Volume (3M)	2.25M	1.90M

Risk-Adjusted Performance

Risk-Return Positioning

A and ALNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
Sharpe Ratio (1Y)	0.56	-1.27
Sortino Ratio (1Y)	0.96	-1.45

Profitability

ROE (TTM)

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Agilent (A) at 20.97% also sits in the top quartile.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max: 109.18%
A: 20.97%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

ALNY: 138.07%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Agilent (A) at 19.53% and Alnylam Pharmaceuticals (ALNY) at 52.85% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A: 19.53%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

ALNY: 52.85%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Alnylam Pharmaceuticals (ALNY) at 23.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max: 83.12%
A: 25.56%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Max: 83.12%
ALNY: 23.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
ROE (TTM)	20.97%	138.07%
ROA (TTM)	8.63%	9.51%
Net Margin (TTM)	19.53%	52.85%
Operating Margin (TTM)	25.56%	23.72%
Gross Margin (TTM)	53.65%	77.28%

Growth

Revenue Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Agilent (A) at 6.73% is closer to the peer norm — faster top-line expansion for ALNY.

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Agilent (A) reports EPS growth of 3.16%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
Revenue Growth (YoY)	6.73%	65.19%
Revenue Growth (3Y CAGR)	0.48%	52.98%
EPS Growth (YoY)	3.16%	--
EPS Growth (3Y CAGR)	3.02%	--

Financial Strength

Current Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
A: 2.05
Min: 0.10

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Max: 25.13
Q3: 12.13
Median: 5.52
ALNY: 2.48
Q1: 2.47
Min: 0.10

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max: 1.42
Q3: 0.65
A: 0.56
Median: 0.15
Q1: 0.02
Min: 0.00

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 1.42
ALNY: 0.83
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
Current Ratio (MRQ)	2.05	2.48
Debt / Equity (MRQ)	0.56	0.83
Net Debt / EBITDA	1.15	-0.57

Dividends

Dividend Yield (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A: 0.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A: 19.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
Dividend Yield (TTM)	0.59%	0.00%
Dividend Payout Ratio (TTM)	19.98%	0.00%

Valuation

P/E Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Agilent (A) at 34.47 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max: 85.34
Q3: 43.46
A: 34.47
Median: 26.69
Q1: 13.30
Min: 0.07

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
ALNY: 7.88
Min: 0.07

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Alnylam Pharmaceuticals (ALNY) at 4.17 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
A: 6.68
Q1: 3.01
Min: 0.01

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Max: 58.18
Q3: 25.77
Median: 7.30
ALNY: 4.17
Q1: 3.01
Min: 0.01

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) at 5.79 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 13.53
A: 6.69
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Max: 13.53
Q3: 6.54
ALNY: 5.79
Median: 3.25
Q1: 1.69
Min: -5.59

Agilent (A) vs. Alnylam Pharmaceuticals (ALNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Alnylam Pharmaceuticals (ALNY)
Metric	A	ALNY
P/E Ratio (TTM)	34.47	7.88
P/S Ratio (TTM)	6.68	4.17
P/B Ratio (MRQ)	6.69	5.79
Free Cash Flow Yield (TTM)	2.15%	1.57%